Yearly STL Archives: 2021

How to Use Halobetasol Propionate and Tazarotene Lotion to Treat Psoriasis

A fixed combination halobetasol propionate and tazarotene lotion (HP/TAZ) was launched in Canada in 2020, to treat moderate to severe plaque psoriasis in adults. With the use of polymeric emulsion technology, there is uniform distribution of HP and TAZ and excipients on the skin and improved skin moisturization.

Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis

A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults.

Psoriasis Education Tool for Patient-Physician Decision-Making About Biologics: A Pilot Study

Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.

Update on Drugs & Devices: November-December 2021

The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).

Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis

The Canadian Skin Management in Oncology Group (CaSMO) developed an algorithm for the reduction of severity and management of acute RD, which follows previous publications from this group that addressed general oncology-treatment related cutaneous adverse events [AEs], prevention, and skin management.

Optimal Use of Crisaborole in Atopic Dermatitis – An Expert Guidance Document

Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).

Labeling Laws for Personal Care Products: Potential Pitfalls for The Consumer

Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as “hypoallergenic“, “sensitive skin“, and ...

Hair Removal Practices: A Literature Review

This article is a general overview of hair removal practices, which have evolved from utilizing waxes and blades, to advanced lasers and electrolysis, with further advancements still being studied

Update on Drugs & Devices: September – October 2021

The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments

Rosacea: An Update in Diagnosis, Classification and Management

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing

Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.

Update on Drugs & Devices: July – August 2021

The update covers: Secukinumab for SC use - Cosentyx® (Novartis), Brincidofovir tablets and oral suspension - Tembexa® (Chimerix), Plasminogen, humantvmh - Ryplazim® (Liminal BioSciences), Halobetasol propionate lotion 0.01% w/w - Bryhali™ (Bausch Health), and Nomacopan for SC use (Akari Therapeutics).

Bimekizumab for Moderate-to-Severe Plaque Psoriasis

Bimekizumab is a novel treatment for moderate-to-severe plaque psoriasis that has shown promising efficacy and safety in clinical trials. By simultaneously targeting two components of the IL-17 pathway, IL-17A and IL-17F, the biologic can downregulate proinflammatory signaling and rapidly improve patients’ skin.

Prurigo Nodularis: Review and Emerging Treatments

Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.

Update on Drugs & Devices: May-June 2021

The update covers: Axatilimab IV injection - SNDX-6352 (Syndax Pharmaceuticals), Binimetinib tablets + encorafenib capsules - Mektovi® + Braftovi® (Pfizer Canada), Encapsulated cell therapy for Fabry disease - SIG-007 (Sigilon Therapeutics) and Oritavancin IV injection - Kimyrsa™ (Melinta Therapeutics).

Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy

Certolizumab Pegol appears to offer a safe and effective psoriasis treatment for patients who are considering pregnancy, pregnant, or lactating based on its pharmacokinetics and available safety data.

Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions

HPV vaccines (Gardasil and Cervarix) may indeed have a therapeutic role in patients who suffer from dermatologic conditions that are associated with various strains of HPV.

Skin Treatments Introduced in 2020

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Drugs & Devices: March-April 2021

The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).

Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients With Oncology Treatment-Related Skin Toxicities

The CaSMO (Canadian Skin Management in Oncology) algorithm focuses on general skincare measures to prevent or reduce the severity of cancer-treatment-related cutaneous toxicities.

Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis

Early clinical trial data indicate the increasing effectiveness and safety of efinaconazole 10% solution use beyond 12 months; application for up to 24 months appears to remain safe even for elderly patients.

2020 Index for Skin Therapy Letter – Dermatology Edition

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Drugs & Devices: January-February 2021

The latest drug & device update covers: Orladeyo™ (BioCryst Pharmaceuticals), KPL-716 (Kiniksa Pharmaceuticals), Sklice® (Arbor Pharmaceuticals) and Picato® (Leo Pharma)

POPULAR